Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bedford Park SA, Australia Clinical Trials

A listing of Bedford Park SA, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

Phase 1 XG005-03 Topical Study

This is a single-blind, placebo-controlled study which will investigate the PK, safety and tolerability of XG005-03 topical formulation, in three ascending concentrations after single and multiple topical applications in healthy subjects. The trial consists of two parts: a single ascending dose (SAD; Part 1) and a multiple ascending dose (MAD; ...

Phase

6.42 miles

Learn More »

A Study of Antolimab (AK002) in Patients With Active Eosinophilic Esophagitis

This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of antolimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of ...

Phase

6.65 miles

Learn More »

Safety Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor agonist HSK21542 in Healthy Volunteers. The study will enroll approximately 50 adults. The anticipated study duration will be up to 6 months.

Phase

6.65 miles

Learn More »

OLE for Patients Enrolled in Phase 2b/3 Study ANAVEX2-73-AD-004

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

Phase

6.65 miles

Learn More »

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

This is a Bayesian adaptive phase 2, multi-center, double-blind, randomized, placebo-controlled, 52-week, dose-ranging study in subjects with active SLE and inadequate response to SOC therapies including oral corticosteroids (OCS), immunosuppressants and immunomodulators. Previous biologic use is allowed with an adequate washout period.

Phase

9.85 miles

Learn More »